

# Development of novel neoadjuvant therapy for triple negative breast cancer (TNBC)

NA Vaccine Institute



ONCOLOGY	Candidate
Product Type	Gene/Cell Therapy & Nucleic acids
Indication	Triple negative breast cancer (TNBC)
Target	N/A
MoA(Mechanism of Action)	NK cells activated by type 1 interferon eliminate circulating triple-negative breast cancer (TNBC) cells.
Competitiveness	Current TNBC therapeutics face limitations due to several factors, including the lack of specific, widely effective targeted therapies and the high risk of resistance to chemotherapy. Currently, patients rely heavily on combination chemotherapy, but alternatives are limited for patients who do not respond to this or who have progressed to metastatic disease. It is well established that interferon (IFN) signaling plays a significant role in the pathogenesis and treatment of triple-negative breast cancer (TNBC). This technology induces different subtypes of interferon by injecting an appropriate dose of an inducer that stimulates interferon production in the body. Our goal is to enhance existing treatments by simultaneously regulating various factors, including innate immunity, acquired immunity, and the tumor microenvironment (TME).
Development Stage	Candidate
Route of Administration	Intramuscular or intratumoral route (TBD)

*Any unauthorized distribution or reproduction of this material is strictly prohibited.*